Increased methylation levels of HOXD3 and GSTP1 are observed in prostate tumors and are correlated with aggressive PCa and/or adverse clinical outcomes [9, 18, 20, 21]. The gene discussed is HOXD3; the disease is posterior cortical atrophy.